Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Krystal Biotech, Inc. KRYS

Healthcare  —  Biotechnology
345.82 0.86 0.25% as of 25 Sep
Market cap
$10.2B
P/E
41.9×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Krystal Biotech, Inc. (KRYS) Business Profile

Updated before January 2025

Company Overview

Krystal Biotech, Inc. (NASDAQ: KRYS) is a cutting-edge biotechnology company specializing in the development and commercialization of gene therapies for rare and debilitating skin diseases. Founded in 2016 by Suma Krishnan and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech has rapidly emerged as a leader in the field of dermatological gene therapy. The company is led by a team of seasoned professionals, including its CEO and President, Krish S. Krishnan, and its founder and Chief Operating Officer, Suma Krishnan. With a mission to transform the lives of patients suffering from genetic skin disorders, Krystal Biotech leverages its proprietary platform to develop innovative treatments that address unmet medical needs.

Core Business Segments

Krystal Biotech focuses on the development of gene therapies for dermatological conditions. Its core business segments include:

1. Gene Therapy for Rare Skin Diseases

Krystal Biotech’s flagship product is Vyjuvek™ (beremagene geperpavec), a topical gene therapy designed to treat dystrophic epidermolysis bullosa (DEB), a rare and debilitating genetic skin disorder. Vyjuvek™ is the first FDA-approved topical gene therapy for DEB and represents a significant breakthrough in the treatment of this condition.

2. Pipeline of Gene Therapies

The company has a robust pipeline of gene therapy candidates targeting various dermatological and non-dermatological conditions. Key pipeline products include:

  • KB105: A gene therapy for treating autosomal recessive congenital ichthyosis (ARCI), a rare genetic skin disorder.
  • KB407: A gene therapy for cystic fibrosis, targeting the underlying genetic cause of the disease.
  • KB301: A gene therapy for aesthetic dermatology, focusing on improving skin quality and reducing signs of aging.

3. Manufacturing and Technology Platform

Krystal Biotech has developed a proprietary gene delivery platform called the Skin TARgeted Delivery (STAR-D) system. This platform enables the efficient delivery of therapeutic genes to the skin, ensuring high levels of safety and efficacy. The company also operates its own Good Manufacturing Practice (GMP)-certified manufacturing facility, Ancoris, which provides end-to-end control over the production of its gene therapy products.

Business Model

Krystal Biotech’s business model is centered around the development, manufacturing, and commercialization of gene therapies. The company generates revenue through the sale of its approved products, such as Vyjuvek™, and through partnerships and collaborations with other organizations. By maintaining control over its manufacturing processes and leveraging its proprietary STAR-D platform, Krystal Biotech ensures the quality and scalability of its products. The company’s focus on rare and underserved markets allows it to command premium pricing for its therapies, further enhancing its revenue potential.

Strategic Direction

Krystal Biotech is committed to expanding its portfolio of gene therapies and exploring new therapeutic areas. Key strategic priorities include:

  • Pipeline Expansion: The company aims to advance its existing pipeline candidates, such as KB105, KB407, and KB301, through clinical trials and regulatory approvals.
  • Geographic Expansion: Krystal Biotech plans to expand the availability of its products to international markets, particularly in Europe and Asia.
  • Sustainability Goals: The company is focused on minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste.
  • Innovation in Gene Therapy: Krystal Biotech continues to invest in research and development to explore new applications of its STAR-D platform and develop next-generation gene therapies.

Competitive Landscape

Krystal Biotech operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Amicus Therapeutics: Focused on developing therapies for rare genetic diseases.
  • Sarepta Therapeutics: Specializes in gene therapies for neuromuscular diseases.
  • Bluebird Bio: A leader in gene therapy for severe genetic disorders and cancer.
  • Editas Medicine: Focused on gene editing technologies.

Despite the competition, Krystal Biotech differentiates itself through its proprietary STAR-D platform, focus on dermatological conditions, and end-to-end control over its manufacturing processes.

Risk Factors

Krystal Biotech faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The development and approval of gene therapies are subject to stringent regulatory requirements, which could delay or prevent the commercialization of its products.
  • Market Dependence: The company’s revenue is heavily reliant on the success of Vyjuvek™ and its pipeline products.
  • Supply Chain Disruptions: Any disruptions in the supply chain could impact the production and distribution of its therapies.
  • Competition: The biotechnology sector is highly competitive, and the emergence of new technologies or therapies could erode Krystal Biotech’s market share.
  • Financial Risks: As a relatively young company, Krystal Biotech may face challenges in securing funding for its research and development activities.

Recent Developments

Krystal Biotech has achieved several milestones in recent years:

  • FDA Approval of Vyjuvek™: In 2023, Vyjuvek™ received FDA approval, marking a significant milestone for the company and the field of gene therapy.
  • Advancements in Pipeline: The company has made progress in clinical trials for KB105, KB407, and KB301, with promising results reported in early-stage studies.
  • Expansion of Manufacturing Capabilities: Krystal Biotech has invested in expanding its Ancoris manufacturing facility to meet the growing demand for its products.
  • Partnerships and Collaborations: The company has entered into strategic partnerships to accelerate the development and commercialization of its therapies.

Investment Considerations

Investors considering Krystal Biotech should weigh the following strengths and risks:

Strengths

  • Innovative Technology: The STAR-D platform provides a competitive edge in the gene therapy market.
  • First-Mover Advantage: Vyjuvek™ is the first FDA-approved topical gene therapy for DEB.
  • Robust Pipeline: A diverse pipeline of gene therapy candidates targeting multiple indications.
  • Strong Leadership: Experienced management team with a proven track record in biotechnology.

Risks

  • Regulatory and Clinical Risks: Uncertainty surrounding the approval and commercialization of pipeline products.
  • Market Competition: Intense competition from other biotech and pharmaceutical companies.
  • Financial Uncertainty: Dependence on external funding to support research and development activities.

Conclusion

Krystal Biotech, Inc. is a pioneering biotechnology company with a strong focus on gene therapies for rare and debilitating skin diseases. With its innovative STAR-D platform, FDA-approved Vyjuvek™, and a promising pipeline of therapies, the company is well-positioned for growth in the rapidly evolving gene therapy market. While challenges such as regulatory risks and market competition remain, Krystal Biotech’s commitment to innovation and patient-centric solutions underscores its potential for long-term success.